CLS-301

N/A

Report date: 2023/08/17 17:07:27
NME

Base Information

Drug NameCLS-301
Drug Alias NameCLS-301
ClassificationSmall molecules
Mechanisms of ActionIntegrin antagonists
TargetsIntegrin
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesClearside Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesClearside Biomedical Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A